Mahacef-XL 200 New Tablet is a combination antibiotic formulation containing Cefixime 200 mg and Dicloxacillin 500 mg, designed for the treatment of a broad spectrum of bacterial infections. Cefixime, a third-generation cephalosporin, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, effective against gram-negative and some gram-positive organisms. Dicloxacillin, a penicillinase-resistant penicillin, targets primarily penicillinase-producing Staphylococcus aureus and other susceptible gram-positive bacteria by disrupting cell wall synthesis. The synergistic action of these two antibiotics provides enhanced coverage against mixed infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and bone infections. Mahacef-XL 200 New Tablet is indicated for use in patients with confirmed or suspected infections caused by susceptible strains, particularly where resistance to single agents is a concern. It should be administered as prescribed by a healthcare professional, with dosage adjusted based on infection severity and patient factors such as renal function. Caution is advised in patients with a history of hypersensitivity to beta-lactam antibiotics. Adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and rarely, hematologic abnormalities. Proper adherence to the prescribed regimen is essential to prevent resistance development and ensure therapeutic efficacy.